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Abstract
Objectives: In this retrospective study, we present a clinical review of our experience with tongue cancer in order
to obtain valid criteria for therapeutic decision-making.
Materials and methods: Between 1980 and 2009, a total of 341 patients with squamous cell carcinoma of the
tongue were treated at our Department. The average follow-up was 5.2 years. 309 patients received surgical
treatment, which was combined in nearly 10% with neoadjuvant and in nearly 20% with postoperative radio
(chemo)therapy. 32 patients were excluded from surgery and received primary radiation.
Results: Local and regional failure occurred in 23.9% and 20.4%, leading to a total failure rate of 37.2% after an
average duration of 1,6 years. N-Status, extracapsular spread and clear margins were identified as the dominant
factors for survival, which was calculated with 54.5% after 5 years.
Conclusions: We recommend categorical bilateral neck dissection in order to reliably remove occult lymph node
metastases. Adjuvant treatment modalities should be applied more frequently in controlled clinical trials and
should generally be implemented in cases with unclear margins and lymphatic spread.
Clinical relevance: This study provides new treatment strategies for primary tumour disease and for tumour
recurrence.
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Introduction
Tongue cancer is the most common malignancy diag-
nosed within the oral cavity, which accounts between 25
and 40% of oral squamous cell carcinomas [1]. Despite
the development of multimodal treatment options, the
prognosis remains relatively poor. Manifest and occult
lymph node metastasis are observed more often than in
any other cancer of the oral cavity [2]. The tongue
seems to be predisposed for malignant invasion due to
its highly muscularized structure and its rich lymphatic
network [3]. Extensive resection with implementation of
elective neck dissection especially in early stages of
tongue cancer has therefore been a source of debate in
recent years [4-6].
Only a limited number of studies have examined lar-
ger series of tongue cancer. Spiro and Strong evaluated
314 patients (1957-1963) with tongue cancer and found
an overall 5-year survival rate of only 42% [7]. In a later
study from the same institution with 412 patients (1969-
1978), Callery et al. noted an increased proportion of
female patients and an increased involvement of the
base of tongue compared to the earlier decade [8]. More
patients received primary and adjuvant radiotherapy,
and elective neck dissection was performed more fre-
quently. Age, sex, and adjuvant therapy did not affect
survival, which remained stable compared to the earlier
decade. However, lower stages of tongue cancer had a
better prognosis when the tumour was located in the
mobile tongue instead of the base of the tongue. In a
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patients (1978-1987), Franceschi et al. demonstrated an
improved overall 5-year survival rate of 65%, although
the distribution of tumour stages was about the same
compared to the preceding 10-year period [9]. Better
survival was related to a more aggressive treatment of
the neck even in early tumour stages and to adjuvant
radiotherapy in advanced tumour stages. A considerable
number of patients had to be upstaged after elective
neck dissection due to occult lymph node metastases.
The number of lymph node metastases turned out to be
of prognostic value.
Since surgical treatment of tongue cancer strongly
affects quality of life, many attempts have been made
during the last decades towards organ preservation,
leading to different treatment strategies with various
combinations of surgery, radiation and chemotherapy
[10]. Pernot et al. reviewed the medical records of 448
patients with tongue cancer who exclusively received
radiation based therapy either as a combination of bra-
chytherapy and external beam radiation or as a combi-
nation of brachytherapy and neck dissection [11]. The
size of the lesion turned out to be the most important
factor for prognosis with an overall 5-year survival rate
of 44%.
The purpose of the present study was to give a precise
description of our experience with surgical based ther-
apy of tongue cancer during the last three decades.
Furthermore, prognostic factors for survival were ana-
lyzed in order to obtain valid criteria for therapeutic
decision-making in clinical routine.
Patients and methods
Between January 1980 and December 2009, a total of
341 patients with squamous cell carcinoma of the ton-
gue were treated at the Department of Oral and Maxil-
lofacial Surgery, Hannover Medical School. Data
concerning patient characteristics, clinical and patholo-
gic tumour characteristics and treatment strategies and
their results were obtained from a retrospective review
of medical records. Informations regarding patient survi-
val and local, regional and distant control were available
for all patients. The average follow-up was 5.2 years.
Statistical analysis for survival was calculated by the
method of Kaplan and Meier. The relationship between
the clinicopathologic variables and survival was assessed
in univariate analysis using the log rank test. For multi-
variate analysis, the Cox proportional hazard model was
used. A value of p ≤ 0.05 was considered to be statisti-
cally significant.
Results
The average age at diagnosis was 58.8 years, ranging
between 19.2 and 96.5 years. There were 226 men and
115 women (male/female ratio = 2/1). The primary site
was the tip of the tongue in 8 cases (2.4%), dorsum of
the tongue in 11 cases (3.2%), the base of the tongue in
91 cases (26.7%) and the lateral border of the mobile
tongue in 231 cases (67.7%). There was a strong correla-
tion between the primary site and the tumour size, with
increasing tumour size towards the base of the tongue.
Tumour extension across the midline was observed in
33 cases (9.7%). 14.5% of tumours were graded as well-
differentiated, 69.6% as moderately-differentiated and
16.0% as poorly-differentiated. Anaplastic carcinomas
were not observed. Nearly half of the patients suffered
from T1-tumours (45.1%), followed by T2-tumours
(32.7%) and T3- and T4-tumours (11.1% each). 309
patients received surgical treatment, whereas 32 patients
were excluded from surgical treatment and received pri-
mary radio(chemo)therapy after biopsy. These patients
refused surgery, were in inappropriate condition for gen-
eral anaesthesia or suffered from inoperable tumour dis-
ease. As a consequence, the proportion of advanced
tumour stages was higher in this group. Detailed infor-
mation of histopathological and clinical staging results
(pT-status/cT-status) of patients with and without surgi-
cal treatment are given in Table 1. Clinical staging
results were based on recorded clinical examinations
and - if present - evaluation sheets of ultrasound (US)
and computed tomography (CT). Data from modern
imaging techniques of initial clinical staging was almost
complete for the second half of the investigation period.
In patients with surgical therapy, the neck was staged
pN0, pN1, pN2 and pN3 in 48.5%, 18.4%, 14.9% and
0.3% of cases. In 55 patients of this group (17.8%) the
neck was staged pNx due to missing surgical therapy of
t h en e c k .A tt h et i m eo fd i a g n o s i s ,l y m p h a d e n e c t o m y
Table 1 Histopathological and clinical staging results
(pT-/cT-status) of patients with surgical treatment and
patients with radiotherapy
group T-stage n % valid%
pT1 150 48,5 49,0
surgical treatment pT2 108 35,0 35,3
pT3 31 10,0 10,1
(n = 309) pT4 17 5,5 5,6
total 306 99,0 100,0
missing 3 1,0
total overall 309 100,0
cT1 0 0,0 0,0
non-surgical cT2 1 3,1 3,7
cT3 6 18,8 22,2
treatment (n = 32) cT4 20 62,5 74,1
total 27 84,4 100,0
missing 5 15,6
total overall 32 100,0
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patients without surgical therapy, the presence of lym-
phatic spread was higher. In 10 patients of this group
(31.3%) the neck was staged cNx due to missing clinical
data. Detailed information of histopathological and clini-
cal staging results (pN-status/cN-status) of patients with
and without surgical treatment are given in Table 2. for
both groups, there was a strong correlation between the
tumour size at the primary site (T-status) and the pre-
sence of lymphatic spread (N-status). In the group of
patients with surgical treatment, histologically assessed
contralateral lymph node metastases were only observed
in 9 patients (2.9%) of whom 5 patients had 1, 3 patients
had 2 and 1 patient had 3 lymph node metastases on
the contralateral side. Extracapsular spread was observed
in 12.7% of patients with histologically assessed lymph
node involvement, which strongly correlated with the
degree of lymphatic spread (pN-status).
9.7% of the operated patients received neoadjuvant
radiochemotherapy (30Gy/Cisplatin) prior to surgery,
which was performed via a transoral (55.7%) or trans-
mandibular approach (32.6%) or in pull-through techni-
que (10.4%). 4 patients (1.3%) only received bilateral
neck dissection, while the tumour at the primary site
was radiated without surgery. Clear margins were
achieved in 91.3% of the operated patients. On the ipsi-
lateral neck, 44% of the operated patients received a
comprehensive neck dissection, while 38.2% only
received lymphadenectomy of level I-III and 17.8% no
surgical therapy. On the contralateral neck, only 1.3% of
these patients received a comprehensive neck dissection,
while 36.6% still received lymphadenectomy of level I-III
and the majority of 62.1% no surgical therapy. 19.5% of
patients in the surgical group received postoperative
radiation due to unclear margins, extensive tumour
growth at the primary site, massive lymph node
involvement or extracapsular spread, reflecting the
scope of changing indications for radiotherapy during
the past 30 years.
Local recurrence and regional recurrence were
observed in 74 patients (23.9%) and 63 patients (20.4%)
of the operated group, leading to total locoregional
recurrence in 115 patients (37.2%) after surgical based
therapy. In patients with regional recurrence, secondary
lymph node metastases were located on the ipsilateral
neck in 73.8%, on the contralateral neck in 18.0% and
on both sides of the neck in 8.2%. Locoregional recur-
rence occurred after an average duration of 1.6 years
after initial treatment. 10.9% of all patients (surgical plus
non-surgical group) developed a second malignant dis-
ease during follow-up.
The overall survival rates after 1, 2, 5 and 10 years
(including the surgical and non-surgical group) were
calculated with 80.5%, 67.7%, 50.6% and 36.6%. The sur-
vival rates of the surgical group were calculated with
83.8%, 71.5%, 54.5% and 39.6%, whereas the survival
rates of the non-surgical group were calculated with
47.8%, 30.7%, 13.7% and 6.8% (Figure 1, log rank p <
0.001). A detailed list of calculated survival rates for dif-
ferent T- and N-stages are given in Table 3 and Table
4. In univariate analysis (log rank), the following factors
were identified as prognostic factors for survival after
surgical based therapy: tumour site (Figure 2, p =
0.005), grading (Figure 3, p = 0.004), pT-status (Figure
4, p < 0.001), pN-status (Figure 5, p < 0.001), number of
lymph node metastases (Figure 6, p < 0.001), extracap-
sular spread (Figure 7, p < 0.001) and clear margins
(Figure 8, p < 0.001). Tumour extension across the
Table 2 Histopathological and clinical staging results
(pN-/cN-status) of patients with surgical treatment and
patients with radiotherapy
group N-stage n %
pN0 150 48,5
pN1 57 18,4
surgical treatment pN2 46 14,9
(n = 309) pN3 1 0,3
pNx 55 17,8
total 309 100,0
cN0 0 0,0
non-surgical treatment cN1 8 25,0
(n = 32) cN2 13 40,6
cN3 1 3,1
cNx 10 31,3
total 32 100,0
Figure 1 Survival of patients with surgical treatment and
patients with primary radio(chemo)therapy (log rank p <
0.001).
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tases (p = 0.922) did not show significant values. For N-
status, extracapsular spread and clear margins, signifi-
cant values were also confirmed in multivariate analysis
(Cox proportional hazard model).
Survival rates after 1, 2, 5 and 10 years for patients
with and without local recurrence, regional recurrence
and locoregional recurrence show significantly reduced
survival for patients with tumour recurrence (Figure 9,
log rank p < 0.001). Treatment modalities for tumour
recurrence included singular surgery, surgery in combi-
nation with radiotherapy, singular radiation and com-
bined radiotherapy, demonstrating a significant better
prognosis when surgery was involved (Figure 10, log
rank p < 0.001).
Discussion
For many head and neck cancer patients, treatment con-
sists of both chemotherapy and radiation therapy given
simultaneously. This type of treatment is intensive and
often results in serious and sometimes permanent
damage to a patient’s ability to swallow and hence, abil-
ity to eat a normal diet for the remainder of their lives.
Table 3 Survival rates of patients with different pT-stages
(surgical group)
pT-status years %
1 91,9%
pT1 2 85,3%
5 70,2%
10 56,5%
1 80,9%
pT2 2 62,1%
5 42,7%
10 25,2%
1 63,0%
pT3 2 48,5%
5 21,0%
10 16,8%
1 64,7%
pT4 2 52,9%
5 44,1%
10 26,5%
Table 4 Survival rates of patients with different pN-
stages (surgical group)
pN-status years %
1 91,2%
pN0 2 83,2%
5 68,9%
10 49,6%
1 76,4%
pN1 2 60,7%
5 38,7%
10 24,8%
1 58,1%
pN2 2 26,6%
5 16,1%
10 8,1%
pN3 1 0,0%
2 0,0%
5 0,0%
10 0,0%
pNx 1 92,7%
2 87,1%
5 62,7%
10 48,7%
Figure 2 Suvival of patients with different tumour sites (log
rank p = 0.005).
Figure 3 Survival of patients with different tumour grading
(log rank p = 0.004).
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within the range of locoregional recurrence rates
decribed by other authors, which are quoted between 16
and 42% [12-17]. According to the literature, adjuvant
treatment modalities seem to improve locoregional con-
trol. Patients undergoing a targeted chemora- diation
protocol for head and neck cancer lost about 10% of
their pretreatment weight and had a decline in eating
ability [16,18]. In our study, almost 10% of the operated
patients received neoadjuvant radiochemotherapy prior
to surgery and almost 20% of patients in the surgical
group received postoperative radiation due to unclear
margins, extensive tumour growth at the primary site,
massive lymph node involvement or extracapsular
spread, reflecting the scope of changing indications for
radiotherapy during a period of three decades. Since
patient selection for (neo) adjuvant treatment was not
randomized, the impact of radio(chemo)therapy could
not be determined in our study.
Local failure at the primary site occurred in almost a
quarter of our patients with surgical treatment, although
clear margins were described for more than 90% of
these patients. It is generally accepted that clear margins
reduce local failure, although local control is not guar-
anteed. Byers et al. decribes local failure rates between
15 and 30% in patients with clear margins (> 5 mm dis-
tance to the tumour) and between 50 and 80% in
patients with unclear margins [2]. In oncologic regard, it
Figure 4 Survival of patients with different pT-Stage (log rank
p < 0.001).
Figure 5 Survival of patients with different pN-Stage (log rank
p < 0.001).
Figure 6 Survival of patients with different numbers of
positive lymph nodes (log rank p < 0.001).
Figure 7 Survival of patients with and without extracapsular
spread of positive lymph nodes (log rank p < 0.001).
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should be maintained in tongue cancer.
The dimension of lymphatic involvement seems to
reflect the degree of malignancy in tongue cancer
[19-23]. In multivariate analysis, pN-status and extracap-
sular spread directly influenced survival besides clear
margins. In univariate analysis, further factors showed
prognostic value on the first sight. However, better sur-
vival of patients with tumours of the mobile tongue
were attributed to the higher proportion of advanced
tumour stages in patients with tumours of the base of
the tongue, since these tumours were usually detected
later [24,25]. The size of the tumour alone seemed not
to be of relevance for prognosis as long clear margins
were obtained. This also explains why tumour extension
across the midline alone did not affect survival [26,27].
Furthermore, the statistical distribution of tumour grade
and number of lymph nodes were also associated with
prognostic factors which were later identified in multi-
variate analysis. Age and gender - as described by other
authors - did not influence prognosis in our study [24].
In the literature, the prognostic value of tumour grade
is controversially discussed. Whereas some authors con-
s i d e rt u m o u rg r a d ea sap r o g n ostic factor [24,26-29],
other authors doubt the prognostic value of tumour
grade [12,14,30-32]. It seems reasonable that there are
further prognostic factors, which are still unknown and
currently not detectable by modern imaging and histo-
pathological techniques [33]. Therefore, a clear defini-
tion of high risk groups remains incomplete up to the
present. In current literature, serum and saliva are con-
sidered very useful in the fields of genomics, proteomics,
transcriptomics and metabolomics for generation of
diagnostic and prognostic biomarker signatures [34-36].
However, first studies for oral cancer show that these
techniques seem to have greater potential as a tumor
diagnostic tool for follow-up than for prognostication
[37]. Further validation by multi-institutional studies
and randomized clinical trials are recommended before
these techniques can be translated into clinical practice
for oral cancer [38].
It is generally accepted that oral cancer and especially
cancer of the tongue often shows lymph node involve-
ment even in early stages [Figure 11]. The proportion of
occult metastases is quoted between 24 and 42%
[39-41]. The number of patients with initial lymph node
involvement in our study was low compared to other
Figure 8 Survival of patients with and without clear margins
(log rank p < 0.001).
Figure 9 Suvival of patients with and without locoregional
tumour recurrence (log rank p < 0.001).
Figure 10 Survival of patients with different treatment
modalities for locoregional tumour recurrence (log rank p <
0.001).
Kokemueller et al. Head & Neck Oncology 2011, 3:27
http://www.headandneckoncology.org/content/3/1/27
Page 6 of 9studies [42]. Especially the number of patients with
bilateral lymphatic spread was surprisingly rare, since
bilateral lymph node metastases are observed more fre-
quently by other authors [24,37,38]. This might be
attributed to the reduced proportion of patients in our
study with unilateral and especially bilateral neck dissec-
tion during initial treatment. However, a regional failure
rate in every fifth patient is a clear indicator for too
restrictive surgical management of the neck. The
reduced survival rates of patients with regional failure
shows that a “wait and see” policy on the neck is clearly
not advisable. Many authors therefore recommend elec-
tive neck dissection even in early stages of tongue can-
cer when the neck is clinically staged N0 [17,39,40].
The overall survival rate of our patients with tongue
cancer still lies within the range of survival rates
decriped by other authors, which are quoted between 40
and 65% [7-9,11,24]. We have to keep in mind that our
study reviews a period of three decades and that treat-
ment strategies have changed during this period towards
am o r ea g g r e s s i v ec o u r s e[ 4 3 , 4 4 ] .O nt h eb a s eo fo u r
results with high locoregional recurrence rates even in
early stages of tongue cancer, we generally recommend
extended resections on the primary site and categorical
bilateral lymphadenectomy of at least level I-III in order
to reliably remove occult lymph node metastases which
can not be detected even by modern imaging techni-
ques. In case of an open staging procedure with histolo-
gically approved lymph node metastases during surgery,
a comprehensive neck dissection should complete lym-
phadenectomy [45]. As described before, neck dissection
procedures are only associated with a low morbidity
[46]. Modern reconstructive techniques with microvas-
cular tissue transfer [Figure 12] help to keep functional
impairment after partial glossectectomy tolerable and at
least allow to refill substancial loss of soft tissue after
total glossectomy [47] [Figure 13]. According to our
results, radical surgery also provides considerable survi-
val rates for advanced stages of tongue cancer and
should be recommended as treatment of first choice.
Adjuvant treatment modalities should be applied more
frequently in controlled clinical trials and should gener-
ally be implemented in cases with unclear margins and
lymphatic spread.
In general, treatment strategies for tumour recurrence
follow the same principles than for primary tumour dis-
ease. As already described by Eckardt et al., surgical
intervention seems to be associated with better survival
for patients with recurrent floor of mouth carcinoma,
which was also confirmed by our study for patients with
tongue cancer [48]. Therefore, curative total resection
should be aimed if survival is clearly defined as highest
Figure 11 Toung carcinoma defect of the right toung in a 64
year-old patient following resection of tumor. The
reconstruction is planed with an anterolateral thigh flap (ALT-
flap).
Figure 12 Harvested anterolateral thigh flap (ALT-flap) based
on the perforator vessels of the descending branch of the
lateral circumflex femoral artery for reconstruction of the right
toung.
Figure 13 Reconstructed defect of the toung. Final result of
the anterolateral thigh flap (ALT flap) after 6 month.
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matic loss of life quality needs to be discussed individu-
ally with every patient. If recurrent tumour disease
seems to be unresectable, subtotal tumour reduction
can be discussed in order to improve the starting posi-
tion for adjuvant treatment modalities in an interdisci-
plinary treatment concept. In general, however,
mutilations caused by surgical interventions should be
minimized in these cases in order to preserve the great-
est amount of life quality as long as possible.
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